Dr. Martell has served concurrently as Assistant Clinical Professor of Oncology at Yale University School of Medicine and Staff Physician at the Veterans Affairs hospital, and he also worked at Bayer Pharmaceutical Division, where he oversaw the Phase I and Phase II studies for BAY 43-9006 (Sorafenib, a RAF Kinase/VEGF/PDGF inhibitor) and the post-marketing clinical development of Viadur. He received his B.A. degree in chemistry from Kalamazoo College, his Ph.D. degree in pharmacology from the University of Michigan, and his M.D. degree from Wayne State University. He completed his internal medicine internship and residency and medical oncology fellowship at Duke University Medical Center, where he was subsequently appointed Assistant Professor, Department of Medicine, Geriatrics and Medical Oncology.
“I am pleased to be joining Curis’ board of directors, particularly at this exciting time for the company, with Curis’ collaborator Genentech’s recent NDA submission for Hedgehog pathway inhibitor vismodegib and an impressive portfolio of targeted cancer drug candidates,” said Dr. Martell. “I look forward to leveraging my expertise in cancer therapies, including direct experience with some of the core molecules targeted by Curis’ proprietary pipeline, such as EGFR, Her2 and HDAC, to help the company continue to advance its compelling development programs.”
About Curis, Inc.
Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. Curis is building upon its previous experiences in targeting signaling pathways, including the Hedgehog pathway, in its effort to develop proprietary targeted cancer programs. For more information, visit Curis' website at www.curis.com.Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the expected contributions of Dr. Martell, and the prospects of vismodegib and the Company’s pipeline of drug candidates under internal development. Forward-looking statements used in this press release may contain the words "believes", "expects", "anticipates", "plans", "seeks", "estimates", "assumes", "will", "may," “could” or similar expressions. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties, assumptions and other important factors that may cause actual results to be materially different from those indicated by such forward-looking statements including, among other things the risks relating to the Company’s business, operations, financial condition and future prospects that are discussed in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2011 and other filings that Curis periodically makes with the Securities and Exchange Commission.